1. ACOG Practice Bulletin. (April 2005). Clinical management guidelines for obstetrician-gynecologists. Number 61. Human papillomavirus. Obstet. Gynecol. 105(4), 905–918.
2. Androphy, E.J., Hubbert, N.L., Schiller, J.T., and Lowy, D.R. (1987). Identification of the HPV16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines. EMBO J. 6:989–992.
3. Arbeit, J.M., Howley, P.M., and Hanahan, D. (1996). Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc. Natl. Acad. Sci.USA 93(7):2930–2935.
4. Azoury-Ziadeh, R., Herd, K., Fernando, G.J., Lambert, P., Frazer, I.H., and Tindle, R.W. (2001). Low level expression of human papillomavirus type 16 (HPV16) E6 in squamous epithelium does not elicit E6 specific B-or T-helper immunological responses, or influence the outcome of immunisation with E6 protein. Virus Res. 73(2):189–199.
5. Baldwin, P.J., van der Burg, S.H., Boswell, C.M., Offringa, R., Hickling, J.K., Dobson, J., Roberts, J.S., Latimer, J.A., Moseley, R.P., Coleman, N., Stanley, M.A., and Sterling, J.C. (2003). Vaccinia-expressed human papillomavirus 16 and 18 E6 and E7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin. Cancer Res. 9(14):5205–5213.